Abbvie Inc

Change company Symbol lookup

Select an option...

ABBV Abbvie Inc

XPL Solitario Zinc Corp

DD Dupont De Nemours Inc

RLJ RLJ Lodging Trust

TTEXF Bullion Gold Resources Corp

FRLN Freeline Therapeutics Holdings PLC

PCQ PIMCO California Municipal Income Fund

WULF Terawulf Inc

USB-A US Bancorp

DBTX Decibel Therapeutics Inc

Go

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rallied 2.57% to $136.87 Friday, on what proved to be an all-around favorable trading session for the stock...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 3.28% to $133.44 Thursday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rose 1.11% to $137.96 Wednesday, on what proved to be an all-around poor trading session for the stock market...(MarketWatch)

At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg])met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than...(PR Newswire)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slumped 0.81% to $136.44 Tuesday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 0.76% to $137.56 Friday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) shed 1.79% to $138.62 Thursday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 0.96% to $141.15 Wednesday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

Five-year results from SELECT-COMPARE evaluating the efficacy and safety of RINVOQ(R) (upadacitinib) and HUMIRA(R) (adalimumab), both in combination with methotrexate (MTX), are reported for adult patients with moderate to severely active rheumatoid...(PR Newswire)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slipped 1.64% to $142.52 Tuesday, on what proved to be an all-around dismal trading session for the stock...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 0.14% to $144.90 Monday, on what proved to be an all-around mixed trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) rallied 1.16% to $145.11 Friday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

Genmab A/S (Nasdaq: GMAB) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY(TM) (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or...(BusinessWire)

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLYTM (epcoritamab-bysp), as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory...(PR Newswire)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) inched 0.06% higher to $143.44 Thursday, on what proved to be an all-around favorable trading session for the...(MarketWatch)

The co-primary endpoints of endoscopic response (visible reduction of intestinal lining damage) and clinical remission were achieved by significantly more patients treated with RINVOQ (upadacitinib) at week 12 and week 52 versus placebo1 - Clinical...(PR Newswire)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) inched 0.04% higher to $143.35 Wednesday, on what proved to be an all-around great trading session for the stock...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) slid 2.25% to $143.29 Tuesday, on what proved to be an all-around grim trading session for the stock market...(MarketWatch)

This article was automatically generated by MarketWatch using technology from Automated Insights. Shares of AbbVie Inc. (ABBV) dropped 0.38% to $146.59 Monday, on what proved to be an all-around great trading session for the stock market...(MarketWatch)